Pharmaceutical

Amylyx axes ALS drug from market after Phase III failure 

Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.

Apr 7, 2024 - 00:00
Amylyx axes ALS drug from market after Phase III failure 
Last month, Amylyx announced that the Phase III confirmatory trial of ALS drug Relyvrio failed to meet its primary and secondary endpoints.
Read the original article

Tags:

Previous Article

GSK expands Asia-Pacific reach for Trelegy Ellipta with Singapore approval

Next Article

England’s MMR vaccinations up 23% following NHS initiative

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: FDA approves Sage Therapeutics’ rapid-acting medication for postpartum depression but not major depression

STAT+: FDA approves Sage Therapeutics’ rapid-acting med...

Aug 5, 2023

Menarini signs agreement for Astellas’s rheumatoid arthritis therapy

Menarini signs agreement for Astellas’s rheumatoid arth...

Sep 13, 2023

How the political right came to back psychedelics to treat trauma

How the political right came to back psychedelics to tr...

Jul 8, 2023